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La, a 52-kDa autoantigen in patients with systemic lupus erythematosus, was one of the first cellular proteins
identified to interact with viral internal ribosome entry site (IRES) elements and stimulate poliovirus (PV) and
hepatitis C virus (HCV) IRES-mediated translation. Previous results from our laboratory have shown that a
small, yeast RNA (IRNA) could selectively inhibit PV and HCV IRES-mediated translation by sequestering the
La protein. Here we have identified an 18-amino-acid-long sequence from the N-terminal “La motif” which is
required for efficient interaction of La with IRNA and viral 5 untranslated region (5-UTR) elements. A
synthetic peptide (called LAP, for La peptide) corresponding to this sequence (amino acids 11 to 28) of La was
found to efficiently inhibit viral IRES-mediated translation in vitro. The LAP efficiently enters Huh-7 cells and
preferentially inhibits HCV IRES-mediated translation programmed by a bicistronic RNA in vivo. The LAP
does not bind RNA directly but appears to block La binding to IRNA and PV 5-UTR. Competition UV
cross-link and translation rescue experiments suggested that LAP inhibits IRES-mediated translation by
interacting with proteins rather than RNA. Mutagenesis of LAP demonstrates that single amino acid changes
in a highly conserved sequence within LAP are sufficient to eliminate the translation-inhibitory activity of LAP.
When one of these mutations (Y23Q) is introduced into full-length La, the mutant protein is severely defective
in interacting with the PV IRES element and consequently unable to stimulate IRES-mediated translation.
However, the La protein with a mutation of the next tyrosine moiety (Y24Q) could still interact with PV 5-UTR
and stimulate viral IRES-mediated translation significantly. These results underscore the importance of the La
N-terminal amino acids in RNA binding and viral RNA translation. The possible role of the LAP sequence in
La-RNA binding and stimulation of viral IRES-mediated translation is discussed.
The majority of eukaryotic mRNAs contain 5 cap and are
translated by a cap-dependent mechanism that depends on
interaction of the 40S ribosomal subunit with the 5 cap struc-
ture (reviewed in reference 28). In contrast, the RNAs of
picornaviruses, hepatitis C virus (HCV, a flavivirus), cricket
paralysis virus, and a few cellular mRNAs are translated by a
distinct mechanism that differs greatly from cap-dependent
translation (24, 38, 47, 52, 55, 69, 71; reviewed in references 26,
33, and 37). It is now well established that these RNAs recruit
ribosomes not through the 5 end but by virtue of the presence
of internal ribosome entry sites (IRES) within the 5 untrans-
lated region (5-UTR). RNA secondary and tertiary structures
present within the 5-UTR play an important role in ribosome
recruitment (22, 31, 39, 59, 66, 68).
An understanding of the mechanisms of IRES-mediated
translation has come about in recent years due mainly to in
vitro studies of viral IRES elements. In particular, an in vitro
assay for the formation of 48S preinitiation complexes has
demonstrated that the majority of viral IRES elements do not
require eukaryotic initiation factor 4E (eIF-4E), the cap-bind-
ing protein, for complex formation. In addition, various viruses
require different combinations of other canonical initiation
factors; the encephalomyocarditis virus (EMCV) IRES, for
example, requires eIF-4A and a portion of eIF-4G for 48S
complex formation, while the HCV IRES does not require
either of these factors (56, 57). Although these studies have
shed light on the minimum required factors for viral IRES-
mediated translation, it is apparent that transacting factors
play an important role in modulating IRES activity. Cellular
proteins such as La, PTB, PCBP2, nucleolin, and unr have
been shown to interact with viral IRES elements and stimulate
IRES-mediated translation (1, 3, 5, 8, 9, 23, 27, 32, 35, 50). It
has been hypothesized that the transacting proteins may act as
RNA chaperones, stabilizing IRES secondary and tertiary
structures to allow efficient translation to take place (6).
La, a 52-kDa autoantigen in patients with systemic lupus
erythematosus, was one of the first cellular proteins identified
to interact with IRES elements and stimulate poliovirus (PV)
and HCV IRES-mediated translation (1, 2, 7, 50, 65). Addi-
tional evidence for the involvement of the La protein in viral
IRES-mediated translation came from studies using a small
yeast RNA (IRNA), which was shown to selectively inhibit PV
and HCV IRES-mediated translation in vitro (14, 16–18).
IRNA has been shown to sequester the La protein, and the
IRNA-mediated inhibition of PV and HCV IRES-mediated
translation can be reversed by the exogenous addition of the
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purified La protein in vitro. Although La stimulates both PV
and HCV IRES-mediated translation, HCV IRES appears to
have a lower requirement of La compared to the PV IRES
(34). In addition to IRNA’s translation-inhibitory effect in
vitro, replication of wild-type (wt) PV and a PV/HCV chimeric
virus containing the HCV IRES was significantly inhibited in
Huh-7 cells constitutively expressing IRNA (16, 44). Similarly,
an RNA sequence (called SELEX RNA) that was selected for
high-affinity binding to the La protein was found to sequester
La and block HCV IRES-mediated translation (2). Also, in-
terferon treatment of cells led to selective inhibition of HCV
IRES-mediated translation, which correlated to a reduced
level of La protein, and transient expression of La in these cells
completely restored the selective inhibition of HCV translation
(62). Taken together, these results provide evidence that La
may be needed for efficient translation of PV and HCV in vivo.
The La protein has also been implicated recently in the trans-
lation of several cellular mRNAs, including the X-linked in-
hibitor of apoptosis protein and BiP mRNA, that are trans-
lated through IRES elements (29, 30, 42). La also interacts
with the human immunodeficiency virus type 1 (HIV-1) TAR
sequence and relieves translational repression by TAR of a
downstream reporter gene (64). Similarly, La has been shown
to alleviate translation inhibition from the EMCV IRES im-
parted by surplus polypyrimidine tract-binding protein (41).
The majority of the La protein is localized in the nucleus and
appears to influence multiple steps in small RNA biogenesis,
including pre-tRNA maturation (70). In addition, La has been
implicated to play important roles in stabilization of nascent
RNAs, nuclear retention of nascent transcripts, and RNA
polymerase III transcription termination. Although primarily
nuclear, cellular stress such as PV infection causes redistribu-
tion of the La protein from the nucleus to the cytoplasm (50),
possibly by removal of the C-terminal nuclear localization sig-
nal by a viral protease (63).
The majority of small RNAs, mostly polymerase III tran-
scripts, bound by the La protein terminate in the sequence
UUUOH (70). However, La also recognizes various RNAs that
do not terminate with 3-UUUOH. The 5-UTR of PV (50),
HCV (1), ECMV (41), Bip mRNA (42), adenovirus VA1 RNA
(21), influenza virus RNA (54), Sindbis virus RNA (53), vesic-
ular stomatitis virus leader RNA (43), U1 RNA (48), telom-
erase RNA (20), and the HIV TAR (12) interact with the La
protein. The full-length La protein contains three putative
RNA recognition motifs (RRMs): the N-terminal 100 amino
acids containing the highly conserved 60-amino-acid-long “La
motif” (called RRM1), followed by an RNA recognition motif
spanning amino acids 101 to 208 (RRM2), and RRM3 (amino
acids 209 to 300). The C terminus of La is highly charged and
contains a homodimerization domain that is required for La’s
ability to enhance PV RNA translation (15). A recent report
that determined the structure of the C-terminal domain of La
(amino acids 225 to 334), however, did not find a dimerization
domain (36). Deletion analyses have defined regions of the La
protein that are required for RNA binding. The N-terminal
fragments of the human protein, consisting of the La motif and
RRM2, bind several RNA substrates with an affinity compa-
rable to that of the full-length protein. Both the La motif and
RRM2 appear critical for RNA binding (25, 40). Although the
isolated La motif does not bind RNA, even small deletions
within the La motif drastically decrease RNA-binding affinity
(12, 25, 40). At high protein concentrations, the La protein
lacking the La motif still binds RNA, suggesting that some
general RNA-binding ability resides within the RRM2 alone. It
is thought that the La motif may increase the affinity of RRM2
for RNA. Previous studies have shown that the N-terminal half
of the La antigen is important for HCV IRES translation-
stimulatory activity, while the C-terminal half interacts with
5-UTR (2). Recent results, however, have indicated that both
the N- and C-terminal halves can interact independently with
the HCV 5-UTR, and efficient translation from the HCV
IRES occurs in the presence of both halves (58).
We demonstrate here that the same region (amino acids 11
to 28) within the La motif that is crucial for binding the PV and
HCV IRES elements is also required for binding of IRNA. We
designed a synthetic peptide (LAP) corresponding to amino
acids 11 to 28 of La and found that the peptide was able to
inhibit IRES-mediated translation in trans. The 18-amino-acid
LAP does not bind RNA directly but appears to block La
binding to IRNA as well as both PV and HCV IRES elements.
Competition UV cross-link studies and translation rescue ex-
periments suggest that LAP inhibits IRES-mediated transla-
tion by interacting with proteins rather than RNA. In order to
further characterize LAP, we have generated several LAP mu-
tants and tested their translation-inhibitory activity in an in
vitro translation assay. Here we demonstrate that a single
amino acid change is sufficient to eliminate the translation-
inhibitory activity of LAP. When this mutation is introduced
into the full-length La protein, the mutant protein is severely
defective in binding to IRES sequence and consequently un-
able to stimulate IRES-mediated translation. We also demon-
strate that the LAP efficiently enters mammalian cells and in-
hibits translation from the HCV IRES element in cell culture.
MATERIALS AND METHODS
Cells. HeLa cells were grown in monolayers in minimum essential medium
(GIBCO/BRL) supplemented with 10% fetal bovine serum. The hepatocellular
carcinoma cells (Huh-7) were grown in RPMI medium (GIBCO/BRL) supple-
mented with 10% fetal bovine serum. Human embryonic kidney 293 cells were
grown in monolayers in Dulbecco’s modified Eagle’s medium (GIBCO/BRL)
supplemented with 10% newborn calf serum.
Peptides. All peptides were synthesized and purified to 95% homogeneity by
the University of California, Los Angeles, Peptide Synthesis Facility. The pep-
tides were dissolved in 100 mM Tris-HCl (pH 8.0) at 5 mg/ml and then diluted
to 1 mg/ml in nuclease-free water for subsequent use in translation assays. For
fluorescein isothiocyanate (FITC) labeling, the peptides were dissolved in phos-
phate-buffered saline (PBS; pH 8.0).
Purification of La and its deletion mutants. Using cDNA clones of the wt La
(pET-La) and mutants (generously provided by Jack Keene, Duke University,
Durham, N.C.) (11), the recombinant proteins were expressed in Escherichia coli
BL21(DE3)/pLysS by inducing for 4 h with 0.4 mM isopropyl--D-thiogalacto-
pyranoside. The cloning strategies for the wt and mutant proteins have been
described previously (12, 40). The La and the La mutants were purified according
to the protocol described previously (65) with some modifications. Briefly, the
cells were lysed by sonication and the lysate was subjected to centrifugation at
12,000  g for 30 min at 4°C. The supernatant was treated with streptomycin
sulfate (3% final concentration) followed by centrifugation as described above.
The supernatant was dialyzed overnight at 4°C against buffer A (25 mM Tris [pH
8.0], 100 mM NaCl) and then loaded onto a DEAE Sephacel column equili-
brated with buffer A. The flowthrough was collected and separated using fast-
performance liquid chromatography with a heparin Sepharose column using a 0
to 1 M NaCl gradient. The fractions containing purified La or La mutants were
pooled and dialyzed against buffer A and stored at 70°C in aliquots.
In vitro transcription. p2CAT (14) plasmid DNA was linearized with BamHI
and in vitro transcribed with SP6 RNA polymerase. The transcribed mRNA was
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purified using phenol-chloroform extraction and ethanol precipitation. The clone
pSDIR (18) was linearized with HindIII and then transcribed with T7 RNA
polymerase in the presence of [-32P]UTP (3,000 Ci/mmol) to generate uni-
formly labeled IRNA. The plasmid encoding the 5-UTR of PV (18) was linear-
ized with HindIII and transcribed with T7 RNA polymerase in the presence of
[-32P]UTP (3,000 Ci/mmol). The plasmid encoding the HCV 5-UTR (16) was
linearized with HindIII and transcribed with T7 RNA polymerase in the pres-
ence of [-32P]UTP (3,000 Ci/mmol). The radiolabeled RNAs were purified
using Quick-Spin RNA columns (Roche), and the integrity was checked by gel
electrophoresis. The capped RNAs were synthesized in the presence of
m7G(5)ppp(5)G cap analogue using an Ampliscribe T7 transcription kit (Ep-
icenter Technologies).
RNA gel shift analysis. Recombinant wt La and its mutants were incubated
with radiolabeled PV 5-UTR (106 cpm), and the protein-nucleotidyl com-
plexes were resolved according to the protocol described previously (4). For the
gel shift competitions, the peptides were preincubated with radiolabeled PV
5-UTR for 10 min at 30°C before adding purified wt recombinant La.
UV cross-link analysis. 32P-labeled IRNA, PV 5-UTR, or HCV 5-UTR RNA
(106 cpm) probes were incubated with recombinant wt La or its mutants for 10
min at 30°C. After binding, the reactions were processed as described previously
(4).
Extract preparation and in vitro translation. Micrococcal nuclease-treated
HeLa cell lysates were prepared as previously described (14, 60). In vitro trans-
lation of p2CAT using HeLa cell extract was performed essentially as described
elsewhere (60). One microgram of the in vitro-transcribed p2CAT RNA was
translated in 80 	g of HeLa cell extract in a 25-	l reaction mixture in the
presence of 25 	Ci of [35S]methionine (800 Ci/mmol; Amersham) and 40 U of
RNasin (Promega). Peptides were added at 20, 40, and 60 	M final concentra-
tion per reaction mixture. In vitro translation in micrococcal nuclease-treated
rabbit reticulocyte lysates (Promega) was performed as previously described
(64). Densitometric quantifications of translation products or gel shift and UV
cross-link products were performed by using the Image J program provided by
the National Institutes of Health.
FITC labeling of peptides and confocal microscopy. Peptides were FITC
labeled using Molecular Probe’s FluoReporter FITC protein labeling kit (F-
6434) according to the manufacturer’s instructions with a slight modification.
After labeling, the peptides were purified using Quick-Spin RNA (Roche).
HeLa cells or Huh-7 cells grown in slide chambers were incubated with a 5 	M
concentration of each peptide overnight. The cell membranes were subsequently
stained for 20 min with a 1:200 dilution of DiIC18 (Molecular Probes) at a
working concentration of 1 mg/ml and then washed three times with PBS.
For staining the nuclei, Hoechst dye was used at a final concentration of 5 	g/
ml for 5 min. The cells were layered with 25 	l of Gelvatol and covered with glass
coverslips. The cells were analyzed in a Leitz confocal laser scanning microscope
system using a 100 oil immersion lens.
Transfection, reporter assay, and LAP treatment of cells. For each transfec-
tion assay, 106 cells (70% confluency) in 30-mm-diameter plates were transfected
with 3 	g of capped dual luciferase reporter RNA as per the manufacturer’s
instructions (Bio-Rad). Before transfection, the cells were pretreated with vari-
ous concentrations of LAP and a control peptide (HIV-1 Tat) for 2 h. Cells were
then washed three times with PBS to remove excess peptide. At 6 h posttrans-
fection, the cell lysates were prepared and analyzed for reporter gene expression
using the Dual Reporter luciferase assay system (Promega). Transfection exper-
iments were performed in triplicate.
RESULTS
Identification of a critical sequence within the amino-termi-
nal La motif that modulates La binding to IRNA and viral
5-UTR. To determine whether the N-terminal amino acid
sequences within the La motif play any role in IRNA binding,
several La deletion mutants were expressed in bacteria and
purified as described in Materials and Methods. The 408-ami-
no-acid-long wt La (Fig. 1A) was purified to near homogeneity
(Fig. 1B, lane 1). Three amino-terminal mutants, 
N10, 
N22,

N28, where the number corresponds to the number of amino
acids deleted from the amino terminus, were purified (Fig. 1B,
lanes 2, 3, and 4, respectively). We also expressed and purified
two carboxy-terminal deletion mutants, 
C214 and 
C158
(Fig. 1B, lanes 5 and 6, respectively).
Previous results from our laboratory had shown that IRNA
inhibited PV and HCV IRES-mediated translation by binding
to several polypeptides, including La (14, 16–18). To deter-
mine which regions of La control its interaction with IRNA,
UV cross-link analysis was performed using La or La mutants
and radiolabeled IRNA (Fig. 2A). After incubation of the
proteins with labeled IRNA, UV light was used to form a
covalent bond between the protein and nucleic acid. The un-
FIG. 1. (A) Schematic representation of wt La and its deletion mutants (map not to scale). The wt La protein consists of 408 amino acids. The
mutants 
N10, 
N22, and 
N28 lack the N-terminal 10, 22, and 28 amino acids, respectively. 
C214 and 
C158 are carboxy-terminal deletions
of 214 and 158 residues, respectively. (B) Coomassie stain of purified recombinant wt La and its deletion mutants. The wt and mutant proteins
were expressed in E. coli and purified by using DEAE Sephacel and fast-performance liquid chromatography–heparin-agarose column chroma-
tography as detailed in Materials and Methods.
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bound RNA was removed by treating the reactions with a
mixture of RNases. Subsequently, the protein-nucleotidyl com-
plexes were resolved on a denaturing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel. As can
be seen in Fig. 2A, IRNA binding to 
N10 La did not change
significantly compared with that of the wt La protein (lanes 2
and 3). However, deletions of 22 and 28 N-terminal amino
acids affected IRNA binding drastically (Fig. 2A, lanes 4 and
5). The C-terminal 158- and 214-amino-acid deletions had no
significant effect on La’s ability to interact with IRNA (lanes 6
and 7). These results suggest that the region of La spanning
amino acids 11 to 22 (or 28) plays a critical role in its interac-
tion with IRNA. Because IRNA was shown previously to com-
pete with both PV and HCV IRES elements for La binding, it
was of interest to determine whether the same N-terminal
amino acids influenced La binding to PV and HCV IRES. UV
cross-link analysis showed a similar pattern of binding of La
and its mutants to both radiolabeled viral 5-UTR RNA probes
(Fig. 2B and C). The 
N22 and 
N28 mutants showed very
little binding to either PV or HCV 5-UTR RNAs (Fig. 2B and
C, lanes 4 and 5). However, there were subtle differences in La
binding between viral UTR sequences and IRNA. For exam-
ple, the N-terminal 10-amino-acid deletion significantly af-
fected La binding to PV 5-UTR compared to that of the wt La
(Fig. 2B, lanes 2 and 3), whereas this deletion had no effect on
IRNA binding (Fig. 2A, lanes 2 and 3). Also, there was re-
duced binding for the C-terminal deletion mutants; deletion of
the C-terminal 185 amino acids significantly altered interaction
of La with the PV 5-UTR (Fig. 2B, lanes 6 and 7). The amount
of wt La cross-linked to HCV 5-UTR was significantly lower
than that with PV 5-UTR and IRNA (Fig. 2A and B, lane 2,
and C, lane 1). Interaction of La with the HCV 5-UTR was
not altered by deletion of the N-terminal 10 amino acids com-
pared to that with the wt La (Fig. 2C, lanes 1 and 2). However,
both C-terminal deletions significantly affected La binding to
the HCV 5-UTR (Fig. 2C, lanes 5 and 6). The results obtained
from the UV cross-link studies were confirmed by gel retarda-
tion analysis (data not shown). These results suggest that the
same region of La (amino acids 11 to 28) modulates its inter-
action with IRNA as well as the PV and HCV 5-UTR.
Inhibition of viral IRES-mediated translation by a peptide
spanning amino acids 11 to 28 of La. We were interested in
determining whether a synthetic peptide derived from the re-
gion of La spanning amino acids 11 to 28 (Fig. 3A), which
appears to modulate the La–viral 5-UTR interaction, could
act as an inhibitor of internal initiation of translation. We
hypothesized that the peptide (LAP) would either bind the
viral IRES and prevent binding of protein factors such as La to
the IRES element or, alternatively, interact with protein fac-
tors preventing their interaction with the viral IRES sequence.
As a negative control, we randomly chose an 18-amino-acid
sequence downstream of the LAP sequence (Fig. 3A, amino
acids 71 to 88). We called this peptide NSP for nonspecific
peptide.
The chemically synthesized purified peptides were tested in
HeLa cell-free in vitro translation assays using p2CAT RNA
template, which contains the PV IRES element fused to the
reporter chloramphenicol acetyltransferase (CAT) gene and
has been used extensively to study viral IRES-mediated trans-
lation (14, 15, 50, 64, 65). LAP was found to inhibit PV IRES-
mediated synthesis of CAT in a dose-dependent manner; CAT
translation was inhibited by approximately 91% of the control
in the presence of 60 	M LAP (Fig. 3B). The NSP, however,
showed slight inhibition at both concentrations (Fig. 3B). We
also tested the effect of LAP on cap-independent versus cap-
dependent translation in HeLa cell lysates by using a capped
bicistronic RNA. From the bicistronic RNA, the CAT protein
is synthesized in a cap-dependent manner, whereas luciferase
is synthesized from the second cistron in a cap-independent
manner. As can be seen in Fig. 3C, synthesis of luciferase was
inhibited 95% at the highest concentration of LAP over the
buffer-treated control (lanes 1 and 4). No significant inhibition
FIG. 2. UV cross-link analysis of wt and mutant La binding to IRNA, PV 5-UTR, and HCV 5-UTR. 32P-labeled IRNA (A), PV 5-UTR (B),
and HCV 5-UTR (C) were incubated with 100 ng of purified La or various La mutants. The RNA-protein complexes were analyzed by SDS-PAGE
after digestion with a mixture of RNases. In lane 8 of panels A and B and in lane 7 of panel C, column-purified proteins from bacteria expressing
the plasmid without the La insert were examined.
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of luciferase was evident at the same concentration of NSP
(lane 2). cap-dependent synthesis of CAT was not affected
significantly at either 40 or 60 	M LAP. These results suggest
that LAP could specifically interfere with IRES-mediated
translation in vitro. Both RNA gel shift and UV cross-link
analyses were used to determine whether LAP inhibited trans-
lation by blocking La binding to RNA. The wt purified recom-
binant La protein was incubated with 32P-labeled IRNA in the
presence of increasing concentrations of unlabeled LAP (Fig.
4, lanes 2 to 4) or NSP (lanes 5 to 7). After binding, the
complexes were resolved on a nondenaturing gel. The purified
full-length La readily formed a gel-retarded complex with the
IRNA probe (Fig. 4A, lane 2). The formation of RNA-protein
complex was inhibited at all concentrations of LAP (Fig. 4A,
lanes 3 and 4). In contrast, the NSP was almost totally inactive
in blocking the RNA-binding ability of La (Fig. 4A, lanes 5 and
6). A band migrating right above the main RNA-protein com-
plex was not specific, since it was not competed out signifi-
cantly by either peptide. This protein was not detected by
Coomassie blue staining of the purified La preparation and
could be a minor contaminant in the preparation (data not
shown). A similar result was obtained when purified La was
used in the UV cross-link assay using 32P-labeled PV 5-UTR;
while LAP inhibited the La–PV 5-UTR interaction by 90%
compared to the control, NSP had no significant effect (Fig.
4B, lanes 2 to 4). These results suggest that the peptide com-
prised of the La amino acids 11 to 28 is capable of blocking
interaction of full-length La with IRNA and PV 5-UTR. Our
repeated attempts to demonstrate direct binding of LAP to
IRNA or viral 5-UTR sequences using a variety of techniques
including RNA gel shift, UV cross-link, and Northwestern
FIG. 3. (A) N-terminal amino acid sequence of wt La. The capital letters correspond to the sequence of LAP (residues 11 to 18) and NSP
(residues 71 to 88). (B) LAP inhibits IRES-mediated translation in vitro. The effect of LAP and NSP on in vitro translation of p2CAT RNA in
HeLa lysates is shown. In vitro translation reaction mixtures contained 1 	g of uncapped in vitro-transcribed p2CAT RNA in the absence of
peptide (lane 1) and with either 40 or 60 	M LAP (lanes 2 and 3) or NSP (lanes 4 and 5) or buffer alone (lane 6). (C) Effect of LAP on
cap-independent versus cap-dependent translation in vitro. In vitro translation reactions in HeLa cell-free lysates programmed with a bicistronic
capped CAT-SL–PV 5-UTR–luciferase (Luc) (where SL indicates a thermodynamically stable stem-loop [51]) RNA was carried out in the
presence of buffer (lane 1), 60 	M NSP (lane 2), and 40 (lane 3) and 60 	M (lane 4) LAP. The arrowheads indicate Luc and CAT proteins.
FIG. 4. LAP inhibits La binding to RNA. (A) Two hundred nano-
grams of purified La protein and uniformly 32P-labeled IRNA were
used in a gel mobility shift assay in the absence (lane 2) and presence
of 60 and 40 	M LAP (lanes 3 and 4, respectively) or 40 and 60 	M NSP
(lanes 5 and 6, respectively), or buffer alone (lane 7). Lane 1 shows [32P]
IRNA without added La. (B) UV cross-link analysis of PV 5-UTR–La
complex. Two hundred nanograms of purified La was incubated with 32P-
labeled PV 5-UTR in the presence of buffer alone (lane 2), 60 	M LAP
(lane 3), or 60 	M NSP (lane 4). Lane 1 is a negative control without La.
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analyses were not successful (data not shown). Thus, we be-
lieve that LAP might interact with La, and this interaction
could possibly interfere with RNA-protein interaction, leading
to inhibition of IRES-mediated translation.
LAP-mediated inhibition of translation from the PV 5-UTR
can be reversed by HeLa cell extract but not by the 5-UTR.
We next examined whether LAP mediated its translation-in-
hibitory effect directly through the PV 5-UTR or through
interaction with or one or more HeLa cell factors needed
specifically for p2CAT RNA translation. To differentiate be-
tween these two possibilities, we added an excess of either
p2CAT RNA or HeLa cell lysate to the translation reaction
mixtures to saturate LAP and possibly restore translation. Un-
fortunately, the HeLa cell translation lysates were sensitive to
high levels of protein and RNA, so that the addition of a very
large excess of either was not feasible experimentally. How-
ever, it appears that a small increase in the amount of HeLa
cell lysate could overcome the translation inhibition by LAP,
while an increase in the RNA amount could not. Addition of
increasing amounts of the HeLa cell lysate to the translation
reaction mixture in the absence of LAP increased the level of
translation from the p2CAT template by approximately 30% of
the control (Fig. 5A, compare lane 1 with lanes 2 to 4). Addi-
tion of LAP to the reaction mixture containing no additional
HeLa lysates showed approximately 70% inhibition of transla-
tion compared to the control (compare lanes 5 and 1). Trans-
lation inhibition by LAP could be almost completely overcome
by increasing the amount of HeLa cell lysate (compare lanes 6
to 8 with lane 5). Translation was restored to almost 95% of
the corresponding control at the highest concentration of
HeLa lysates (Fig. 5A, lanes 4 and 8). Addition of two-, four-,
and sixfold increases of p2CAT RNA to the translation reac-
tion mixture in the absence of LAP increased the level of
translation by 20 to 35% compared to the control (Fig. 5B,
compare lanes 2 to 4 with lane 1). Over the same range of
RNA concentrations, the inhibitor remained active (Fig. 5B,
lanes 6 to 8), indicating that the RNA was not the direct target
of the inhibitor. These results suggest that translation inhibi-
tion by LAP could be mediated through components (possibly
protein factors) in the HeLa cell lysate. The inhibition of
translation observed in the presence of excess RNA template
(Fig. 5) could be due to sequestration of limiting factors re-
quired for IRES-mediated translation.
LAP is capable of entering cells. To determine whether LAP
inhibits viral IRES-mediated translation in vivo, we first
needed to examine LAP’s ability to transduce cells. LAP and
NSP were FITC labeled. Huh-7 cells were incubated with the
labeled peptides overnight, and then the membranes were
stained with DiIC before analyzing the cells using laser scan-
ning confocal microscopy. As a control, the cells were also
incubated with unconjugated FITC. We found that LAP-FITC
entered the cells (Fig. 6A), while unconjugated FITC and
NSP-FITC did not enter the cells (Fig. 6C and D, respectively).
LAP appeared to be localized within the cytoplasm of the cell.
To confirm cytoplasmic localization of LAP, we incubated
Huh-7 cells with LAP-FITC and then stained the nuclei with
Hoechst dye. As is apparent from Fig. 6B, LAP localized pre-
dominantly to the cytoplasm. Although not shown here, similar
results were obtained with HeLa cells compared to Huh-7 cells
(data not shown).
To determine the rate of LAP entry into the cells, Huh-7
cells were incubated with LAP-FITC for various times and
cells were then examined by flow cytometry. We found that by
1.5 h nearly 100% of the cells had internalized LAP (Fig. 6E).
As expected, NSP-FITC was not detected at all in the cells
tested. We also found that LAP-FITC entered cells at 4°C, but
at a slightly slower pace (30% slower) (data not shown), there-
fore making it unlikely that the peptide was being endocytosed.
Inhibition of HCV IRES-mediated translation by LAP. To
test the possibility that LAP could inhibit IRES-mediated
translation in vivo, we used a T7-Renilla firefly luciferase bi-
cistronic construct with a stable stem-loop incorporated before
the HCV 5-UTR to prevent ribosome readthrough (67). In
vitro transcription from this construct by the T7 RNA poly-
merase in the presence of a cap analogue produces a bicis-
tronic RNA, which is capped at the 5 terminus. Following
transfection of this RNA into Huh-7 cells, the synthesis of
Renilla luciferase from the first cistron is mediated by cap-
FIG. 5. Reversal of LAP-mediated inhibition of p2CAT RNA translation by HeLa cell lysates. (A) Uncapped p2CAT RNA was translated in
50 	g of HeLa cell-free lysate in the absence (lanes 1 to 4) or presence (lanes 5 to 8) of 60 	M LAP. Additional HeLa cell extracts in the amount
of 15 	g (lanes 2 and 6), 30 	g (lanes 3 and 7), and 60 	g (lanes 4 and 8) were included in the reaction mixtures. (B) Uncapped p2CAT RNA
was translated in the absence (lanes 1 to 4) or presence (lanes 5 to 8) of 60 	M LAP. An additional twofold (lanes 2 and 6), fourfold (lanes 3 and
7), and sixfold (lanes 4 and 8) molar excess of p2CAT RNA was added in the translation reaction mixtures.
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dependent translation, while synthesis of firefly luciferase oc-
curs in a cap-independent manner involving the HCV IRES
upstream of firefly luciferase. The Huh-7 cells were preincu-
bated for 2 h with increasing amounts of wt LAP or the HIV-1
Tat peptide (as a negative control) before reporter RNA trans-
fection. Previous studies have shown that amino acid residues
47 to 57 of the HIV-1 Tat protein can freely enter mammalian
cells (61). Although a mutant LAP could have served as a
better negative control in this experiment, we were unable to
use any of the LAP mutants since all the LAP mutants either
had totally lost their ability or were highly inefficient to enter
cells (see Table 2). Also, a “scrambled” peptide having the
same amino acid composition as LAP was neither active in
FIG. 6. LAP efficiently enters the cytoplasm of Huh-7 cells. Huh-7
cells were incubated overnight with 5 	M FITC-labeled LAP (green)
(A), 5 	M unconjugated FITC (C), or 5 	M FITC-NSP (D). The cell
membrane is stained (orange) with DiI. Cells were visualized by con-
focal microscopy as described in Materials and Methods. (B) Huh-7
cells were incubated overnight with LAP-FITC (green) as described
above. The nuclei were stained with Hoechst dye (blue). In this sample,
cell membrane was not stained with DiI. (E) Kinetics of LAP cell
entry. HeLa cells were incubated with 5 	M LAP-FITC (diamonds) or
NSP-FITC (squares). At various time points the cells were washed and
harvested and then analyzed by flow cytometry. The graph shows an
average of three sample wells per time point.
VOL. 78, 2004 VIRAL TRANSLATION INHIBITION BY A PEPTIDE 3769
inhibiting translation nor could it enter cells efficiently. As can
be seen in Fig. 7A, HCV IRES-mediated synthesis of firefly
luciferase was inhibited almost in a linear fashion with increas-
ing concentration of wt LAP. While 50% inhibition was ob-
served at 12 	g of LAP/ml, almost 85% of firefly luciferase
synthesis was inhibited at 25 	g/ml. No significant inhibition of
cap-dependent synthesis of Renilla luciferase was apparent at
lower concentrations of LAP. At the highest concentration
tested (50 	g/ml), over 95% inhibition of firefly luciferase was
observed, while Renilla luciferase was reduced by 37% com-
pared to the control. There was no significant inhibition of
either firefly or Renilla luciferase activity in cells treated with
the Tat peptide compared to that observed with LAP (Fig. 7B).
These results suggest that LAP is capable of inhibiting HCV
IRES-mediated translation from a bicistronic RNA in cell cul-
ture.
Amino acid residues critical for translation-inhibitory ac-
tivity of LAP. The N terminus of all known La proteins con-
tains the approximately 60-amino-acid-long La motif, which is
highly conserved among various species (70). Table 1 shows a
comparison of LAP amino acid sequences (amino acids 11 to
28) from various species. A close examination of this sequence
revealed remarkable homology of this region from species as
diverse as human, mouse, bovine, Xenopus laevis, rat, Caeno-
rhabditis elegans, mosquito, and Drosophila melanogaster. Al-
though there was some variation within the N-terminal 11
amino acids of LAP between distant species, the C-terminal 7
amino acids of the peptide (EYYFGDF) were almost invari-
ant, even between distant species, with the exception of one
C-terminal amino acid change in mosquito and Drosophila and
two C-terminal sequence changes in the C. elegans LAP se-
quence. LAP also contains 10 hydrophobic amino acids. Due
to the presence of a relatively large number of hydrophobic
amino acids, LAP is not readily water soluble at high concen-
trations. In addition to determining the critical amino acids for
LAP’s translation-inhibitory activity, we were interested in
generating an active mutant with higher hydrophilicity to im-
prove solubility. For this reason, we chose to substitute the
hydrophobic amino acids with the polar amino acid glutamine
(Q). Table 2 lists the LAP mutants synthesized, and Fig. 8
examines the effects of these mutations on translation-inhibi-
tory activity of LAP using p2CAT template RNA in HeLa
cell-free translation extracts. Substituting the first three hydro-
phobic amino acids (A11, A12, and L13) with Q only partially
affected the activity of LAP; at 60 	M, the mutant (761) re-
tained 89% activity compared to the wt LAP (Fig. 8A and F).
Substitution of two additional amino acids (A15 and I17; mu-
tant 762) with Q almost completely abolished its translation-
inhibitory activity (Fig. 8A). The mutant peptide (703) with all
four aromatic amino acids (Y23, Y24, F25, and F28) replaced
by Q was found to be totally inactive in blocking translation
(Fig. 8B). Two double substitution mutants, one with both
tyrosines Y23 and Y24 replaced by Q (mutant 771) and the
other with both phenylalanines F25 and F28 replaced by Q
(mutant 772), were found to totally inactive in blocking trans-
lation (Fig. 8B). Thus, the tyrosine and phenylalanine residues
within this highly conserved region of the La motif appear to
be critical for translation-inhibitory activity. We then mutated
the four aromatic amino acids individually. While replacing
Y23 with Q (mutant 741) almost totally abolished LAP activity,
mutation of Y24 (mutant 633) was as effective as the wt LAP
(Fig. 8D). A similar result was obtained when F25 and F28
were mutated individually; while mutant 632 (F25Q) lost al-
most all activity, mutant 631 (F28Q) still retained almost 75%
of wt LAP activity (Fig. 8E). These results suggest that both
Y23 and F25 are critical for the translation-inhibitory activity
of LAP.
We also determined the role of the charged residues on the
activity of the peptide. Mutant 702 (K16Q, H19Q) had activity
FIG. 7. LAP inhibits HCV IRES-mediated translation in vivo. Huh-7 cells were preincubated with various concentrations of LAP (A) or the
HIV-1 Tat peptide (B). After 2.5 h, the cells were washed free of peptides and transfected with the capped bicistronic RNA template. Duplicate
samples of cells treated with FITC-LAP or FITC-Tat peptides were examined to confirm peptide cell entry. At 6 h posttransfection, the cell lysates
were harvested and measured for Renilla and firefly luciferase activities. Representative data from three separate transfections are shown.
TABLE 1. LAP sequences from various species
Species Sequence(amino acids 11 to 28)
Human...............................................................AALEAKICHQIEYYFGDF
Mouse................................................................AALEAKICHQIEYYFGDF
Bovine................................................................AALEAKICHQIEYYFGDF
Xenopus .............................................................LDLDTKICEQIEYYFGDF
Rat .....................................................................AALEAKICHQIEYYFGDF
C. elegans...........................................................DDADQRIIKQLEYYFGNI
Mosquito ...........................................................VSKLEASTIRQEYYFGDA
Drosophila .........................................................TKQERAIIRQVEYYFGDA
3770 IZUMI ET AL. J. VIROL.
comparable to that of the wt LAP (Fig. 8C). In contrast, mu-
tant 701 (E14Q, E22Q, D27Q) had almost no activity. Thus,
negatively charged but not positively charged residues appear
important for the translation-inhibitory activity of LAP.
We also examined the ability of LAP mutants to transduce
cells compared with that of wt LAP. Surprisingly, six out of
seven LAP mutants (701, 762, 703, 771, 772, 741, and 632) that
had lost their ability to inhibit translation also lost the capacity
to enter cells (Table 2). Only mutant 701 could transduce cells;
however, it had a much lower efficiency than wt LAP.
A single amino acid change within the highly conserved La
motif affects both RNA binding and translation stimulation
activity of La. To determine whether the two aromatic amino
acids, Y23 and F25, of LAP are critical for RNA binding and
translation-stimulatory activities of the full-length La protein,
we used site-directed mutagenesis to make the corresponding
changes in the full-length La protein. The first mutants gener-
ated were double substitutions Y23Q-Y24Q (called 
YY) and
F25Q-F28Q (called 
FF). After expression and purification of
mutant polypeptides, the RNA-binding abilities of the mutants
FIG. 8. Effects of various amino acid substitutions on the translation-inhibitory activity of LAP. Various amino acid substitution mutants of
LAP were synthesized chemically and purified to near homogeneity. The mutated amino acids are underlined and are shown in Table 2. The effects
of 20, 40, and 60 	M concentrations of wt and mutant peptides were tested using uncapped p2CAT RNA template in HeLa cell-free lysates as
described in Materials and Methods. The numbers at the bottom of each panel indicate relative translation as determined by quantification of the
CAT polypeptide.
TABLE 2. Translation inhibition and cell entry of
various LAP mutants
Peptide Sequencea Activityc Cell entryd
LAP AALEAKICHQIEYYFGDF  
702 AALEAQICQQIEYYFGDF  
701 AALQAKICHQIQYYFGQF  
761 QQQEAKICHQIEYYFGDF  
762 QQQEQKQCHQIEYYFGDF  
703 AALEAKICHQIEQQQGDQ  
771 AALEAKICHQIEYYQGDQ  
772 AALEAKICHQIEQQFGDF  
741 AALEAKICHQIEQYFGDF  
633 AALEAKICHQIEYQFGDF  
632 AALEAKICHQIEYYQGDF  
631 AALEAKICHQIEYYFGDQ  NDb
a Mutations are indicated by underlined letters.
b ND, not determined.
c Activity was assayed by the ability of the peptides to block p2CAT transla-
tion.
d Cell entry was determined by confocal microscopy of FITC-labeled peptides.
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were compared with that of the wt La (Fig. 9A). Briefly, the
purified proteins were UV cross-linked to uniformly 32P-la-
beled PV 5-UTR RNA. After RNase treatment, the protein-
nucleotidyl complex was analyzed by SDS-PAGE. The same
amount of protein used in the binding assay mixture was also
concurrently loaded on a separate gel for silver staining (Fig.
9B). The purpose of the silver-stained gel was to determine the
relative amounts of the protein used for cross-linking and for
densitometric analysis. Analysis of the 
FF mutant protein by
silver staining showed an additional truncated form of La (Fig.
9B).
When Y23 and Y24 or F25 and F28 were changed to glu-
tamine, the ability to bind PV 5-UTR was reduced by 75%
for 
YY (Fig. 9A, lanes 6 to 8) and almost 83% for 
FF (Fig.
9A, lanes 9 to 11) compared to that of wt La (Fig. 9A, lanes 3
to 5). Based on these results, we decided to generate single
amino acid mutants of La. When Y23 was changed to Q in
full-length La, the binding ability of the protein was reduced by
approximately 75% (Fig. 10A and B, lanes 3 to 4) compared to
that of wt La (lane 2). In contrast, changing Y24 to Q reduced
RNA binding by approximately 28% (lanes 5 to 6). We then
compared the Y23 and Y24 mutant proteins with wt La for
their ability to stimulate PV 5-UTR-mediated translation of
CAT in cell-free translation extracts.
As can be seen in Fig. 10C, the Y23Q mutant had completely
lost translation-stimulatory activity compared to the wt protein
(lanes 1 to 7). In contrast, the Y24Q mutant could still stimu-
late PV 5-UTR-mediated translation almost to the level seen
with the wt protein (lanes 8 to 10). However, higher protein
concentrations of Y24 were required to achieve a comparable
level of translation stimulation seen with the wt La. It should
be noted that translation stimulation by wt La was not linear.
In fact, the Y24Q mutant showed a relatively more linear
response for translation stimulation compared with wt La.
These results suggest that a single tyrosine change within the
La motif can significantly affect both RNA binding as well as
translation stimulation from the PV IRES element.
DISCUSSION
We have shown that an 18-amino-acid-long, highly con-
served sequence encompassing amino acids 11 to 28 of the
human La protein is critical for its interaction with IRNA as
well as PV and HCV 5-UTR sequences. Although the peptide
(LAP) itself does not appear to interact with RNA, it is capable
of blocking the La-RNA interaction as well as viral IRES-
mediated translation both in vitro and in vivo. In contrast, a
peptide chosen randomly from a different region of La (NSP)
or a totally unrelated HIV-1 Tat peptide was almost totally
inactive in blocking viral IRES-mediated translation. Both UV
cross-link and gel retardation studies indicated that LAP in-
terferes with RNA-protein interactions presumably required
for IRES-mediated translation. Rescue of LAP-mediated
translation inhibition by HeLa cell proteins but not by the
5-UTR RNA, as well as the lack of evidence for LAP-RNA
interaction, suggests that translation inhibition by LAP is pos-
sibly mediated through components in HeLa cell lysate. Both
single and multiple amino acid substitutions within LAP have
identified amino acids critical for inhibition of IRES-mediated
translation in vitro. We have shown that two aromatic amino
acids, tyrosine Y23 and phenylalanine F25, are critical for the
translation-inhibitory activity of LAP; replacement of Y23 and
F25 with glutamine almost totally eliminated LAP’s transla-
tion-inhibitory activity in vitro. The full-length La containing
either the Y23Q or F25Q mutation was severely defective in its
interaction with the viral 5-UTR (Fig. 9 and 10). Finally, we
demonstrated that the Y23Q but not the Y24Q substitution in
the full-length La protein was almost totally inactive in stimu-
lating IRES-mediated translation from the PV 5-UTR (Fig.
10).
One of the objectives of this study was to examine whether
IRNA, apparently an IRES-specific inhibitor (17), acted by
competing with PV and HCV IRES elements for the La pro-
tein. Although this study did not address which La residues
actually touch the RNA of interest, these results clearly dem-
onstrate that the same region of La (amino acids 11 to 28)
plays a critical role in binding IRNA as well as PV and HCV
IRES elements. It is clear from the results presented in Fig. 2
that the LA-IRNA interaction does not require the C-terminal
half of La. In contrast, the interaction of La and HCV 5-UTR
FIG. 9. Mutations in full-length La corresponding to LAP mutants
771 and 772 interfere with RNA binding. (A) 32P-labeled PV 5-UTR
RNA was UV cross-linked to 0.5, 1, or 1.5 	g of wt La (lanes 3 to 5),

YY (Y23Q Y24Q; lanes 6 to 8), or 
FF (F25Q F28Q; lanes 9 to 11).
Lane 1 shows the migration of molecular weight markers. Lane 2
contains the labeled probe but no protein. (B) The lower panel is a
silver-stained gel corresponding to the amount of protein used in the
top panel. (C) Amino acid sequences of the wt and mutant La. The
numbers at the bottom of each panel indicate relative band intensity as
measured by densitometric scanning using the NIH Image J program.
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is significantly affected by C-terminal deletions, an observation
consistent with previous results from other laboratories (2, 58).
How does the LAP block IRES-mediated translation in
trans? Gel mobility shift experiments utilizing purified La pro-
tein and 32P-labeled IRNA have shown that LAP can block
efficiently the formation of La-IRNA complex (Fig. 4). Also,
UV cross-linking of La to PV and HCV 5-UTR was almost
totally blocked by LAP but not by NSP (Fig. 4 and data not
shown). Thus, it appears that LAP is able to block RNA-
protein interactions necessary for cap-independent translation.
A simple interpretation of these results is that LAP interacts
with the viral 5-UTR, thus preventing interaction of full-
length La with viral RNA. This possibility seems unlikely, how-
ever, for a number of reasons. First, despite repeated attempts
we have been unable to show direct interaction of LAP with
the 5-UTR (or IRNA) by a variety of techniques, such as gel
shift, UV cross-link, and Northwestern analyses. Our results
are consistent with previous failures of other investigators to
demonstrate an interaction of the isolated La motif (amino
acids 1 to 60), which contains the LAP sequence, with RNA.
Also, a recent study has shown that a truncated La protein
consisting of the first 100 amino acids failed to bind HCV
IRES (58). Secondly, if LAP were interacting with the viral
5-UTR, it would have been possible to rescue LAP-mediated
inhibition of cap-independent translation by increasing the
concentration of the RNA template in the reaction mixture.
We did not observe significant reversal of translation in the
presence of as much as a sixfold excess of template RNA than
that normally used in the translation assay (Fig. 5). In contrast,
the fact that addition of excess HeLa cell lysate could reverse
LAP-mediated inhibition of p2CAT translation suggests pro-
tein-protein as opposed to protein-RNA interaction as the
basis for inhibition of translation by LAP. The protein-protein
interaction may include the La homodimerization domain,
which is required for the function of La in enhancing transla-
tion of PV RNA (15). Indeed, the La protein has been shown
to exist predominantly as a dimer under native conditions. Like
LAP, the La dimerization domain (amino acids 226 to 348) was
found to specifically block PV 5-UTR-mediated translation.
The results of Craig and coworkers (15) suggest that formation
of functional La dimers requires both monomers to retain
RNA-binding activity. It remains to be seen whether LAP can
directly interact with La or other RNA-binding proteins that
enhance IRES-mediated translation.
The full-length La protein contains three RNA-binding do-
mains: RRM1 (approximately amino acids 1 to 100), RRM2
(approximately amino acids 101 to 208), and RRM3 (approx-
imately amino acids 209 to 300). Previous studies have shown
that the N-terminal half of La containing RRM2 is largely
responsible for interaction with PV and HCV IRES elements
(58, 65). RRM3 has also been shown to interact with the HCV
IRES element; however, this interaction appears to be much
weaker than that with RRM2 (58). Results presented in this
paper clearly demonstrate the importance of individual amino
FIG. 10. A single amino acid change in full-length La interferes with RNA binding and translation stimulation. (A) PV 5-UTR was UV
cross-linked to 0.5 	g of wt La (lane 2), 0.5 and 1 	g of Y23 (Y23Q; lanes 3 and 4), or 0.5 and 1 	g of Y24 (Y24Q; lanes 5 and 6). Lane 1 contains
no protein. (B) Silver-stained gel corresponding to the amount of protein used in the UV cross-link analysis. (C) Effects of wt and mutants 741
(Y23Q) and 633 (Y24Q) on p2CAT translation in reticulocyte lysates. In vitro translation from the p2CAT RNA was performed in the absence
(lane 1) or presence of 0.5 (lanes 2, 5, and 8), 1.0 (lanes 3, 6, and 9), or 1.5 (lanes 4, 7, and 10) 	g of wt La (lanes 2 to 4), Y23Q (lanes 5 to 7),
and Y24Q (lanes 8 to 10). The numbers at the bottom of each lane indicate the fold stimulation of translation compared to the control (lane 1)
without added La. (D) Sequences of the wt and mutant La. The Y23Q and Y24Q mutations were confirmed by sequencing the entire La cDNA.
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acids within the La motif (RRM1) in La’s interaction with viral
5-UTR elements and IRNA. Even a single amino acid change
in this region drastically affected La’s ability both to bind RNA
and stimulate translation from the PV 5-UTR (Fig. 10). Al-
though RRM1 does not interact with RNA, it clearly plays an
important role in recognition of 3-UUUOH-containing RNAs
(49). It has also been demonstrated that N-terminal La dele-
tion mutants consisting of amino acids 22 to 408 and 28 to 408
had decreased affinity for HIV leader RNA (12). Additionally,
deletion of the N-terminal 19 amino acids of La altered its
binding to 3-UUUOH-containing RNA and that of the first 28
residues totally abolished RNA binding (D. J. Keenan, per-
sonal communication). These results along with the data pre-
sented here suggest an important role of the La motif (RRM1)
in modulating RNA binding by RRMs 2 and 3. Although the
RRM1 does not directly contact RNA, it may somehow regu-
late the access of the RNA substrate to La RRM 2 and RRM3.
For example, there may be subtle or transient interactions
between RRM1 and RNA to position RRM2, resulting in a
stable interaction of RRM2 with the RNA. Alternatively, in-
teraction of RRM1 with another region of La (within the same
molecule or between two molecules) could facilitate binding of
RRM2 to the RNA. Mutations such as Y23Q and F25Q within
RRM1 may interfere with such activity, leading to a lack of
RNA binding. Determination of the three-dimensional struc-
ture of the La-IRNA complex should shed light on the func-
tions of various La RRMs.
When the carboxy-terminal tyrosines (Y23 and Y24) and
phenylalanines (F25 and F28) of LAP were mutated in tandem
or as a group, a significant decrease in translation activity
resulted (Fig. 8). When the amino acids were individually mu-
tated, Y23 and F25 appeared to be more critical for LAP
activity than the Y24 and F28 residues (Fig. 8). These residues
correspond to a region that is highly conserved among La
homologues (Table 1). Two mutant peptides, QQQIEYYFG
DFQQ and QQQIEYYFGDFNL, were synthesized to span the
highly conserved region to determine if a smaller sequence still
inhibited PV 5-UTR-mediated translation. We found the
smaller peptides had no activity in the in vitro translation assay
(data not shown). Thus, the amino-terminal residues probably
contribute structurally to LAP’s activity. Protein structure-pre-
dicting algorithms predict the conformation for residues 11 to
21 of LAP as an -helix. In mutant 761 (A1Q, A2Q, and L3Q)
the predicted -helix structure has been reduced to residues 11
to 18, and in mutant 762 (A1Q, A2Q, L3Q, A5Q, and I7Q) the
-helix has been reduced to residues 11 to 15. Perhaps it is the
shortening of the -helix by 50% that eliminates activity of
mutant 762 (Fig. 9). The critical region of LAP consisting of
residues Y23, Y24, F25, and G26 is predicted to form a -re-
gion (13) and has a surface probability index of zero. This
suggests that the peptide might be forming a shallow pocket for
interacting with a substrate (RNA or protein). The predicted
structure of mutants 703 (Y23Q, Y24Q, F25Q, and F28Q), 771
(F25Q and F28Q), and 772 (Y23Q and Y24Q) show an ab-
sence of -region and an increase in the surface probability
index, suggesting disruption of the pocket, perhaps leading to
loss of activity. The computer-generated algorithms were not
successful in determining structural differences between mu-
tants 632 (F25Q) and 631 (F28Q) or between 741 (Y23Q) and
633 (Y24Q). Perhaps circular dichroism or nuclear magnetic
resonance spectroscopy could elucidate the structure of LAP
and its mutants.
Although all the LAP mutations that interfere with its ability
to block p2CAT translation (Table 2) have not been tested
with respect to their effects in the full-length La protein, there
appears to be good correlation at least with the mutants tested.
For example, the Y23Q mutation (but not the Y24Q mutation)
is defective in both LAP and full-length La; the LAP with this
mutation is defective in inhibiting translation from the PV
5-UTR (Fig. 8), and the same mutation in the full-length La
protein severely interferes with its RNA-binding and transla-
tion-stimulatory activities (Fig. 10). Similarly, the F25Q substi-
tution (but not the F28Q substitution) has similar effects on
both LAP and La functions (Fig. 8 and 9 and data not shown).
These results suggest that Y23 and F25 have similar roles in
LAP-mediated inhibition of translation and La RNA binding
and translation stimulation. However, it must be emphasized
that the mechanism of action of LAP could be very different
than the role these residues play in the intact La protein,
particularly when it is taken out of context of full-length La. It
is worth mentioning in this context that LAP-mediated inhibi-
tion of p2CAT translation could only be partially rescued by
the purified La protein (data not shown). However, there was
total reversal of LAP-mediated translation inhibition by HeLa
cell-free translation extracts (Fig. 5), suggesting that HeLa cell
proteins other than La are likely to be involved in LAP-in-
duced inhibition of PV 5-UTR-mediated translation. Our pre-
liminary experiments have shown that binding of a number of
HeLa cell proteins, including La, to labeled PV and HCV
5-UTRs was specifically inhibited by LAP (data not shown).
Thus, both translation rescue and RNA-binding data strongly
suggest involvement of other transacting proteins in LAP-me-
diated inhibition of viral translation. Future studies will exam-
ine if LAP (or the LAP sequence in the full-length La protein)
is involved in protein-protein interaction.
Experiments conducted with FITC-conjugated LAP clearly
demonstrated that LAP entered cells (at 37°C), while FITC
alone or FITC-conjugated NSP were unable to enter cells (Fig.
6). The majority of LAP was found to localize in the cell
cytoplasm. At this time we do not know how LAP enters cells.
We believe LAP is not endocytosed into cells, because even at
4°C LAP entered cells, although at a lower pace compared to
that at 37°C (data not shown). Additional experiments will be
required to fully understand the mechanism of LAP cell entry.
One interesting observation from the LAP mutagenesis study
was that almost all mutations that interfered with its transla-
tion-inhibitory activity were also found to interfere with its
ability to enter cells (Table 2). Only one mutant, LAP 701,
which had lost translation-inhibitory activity, could still trans-
duce cells, albeit with lower efficiency than the wt LAP. We do
not know the precise reason for the requirement of the same
amino acid residues for two apparently unrelated functions of
this peptide. It is of interest that other peptides termed PTDs
(for protein transduction domain) that can enter mammalian
cells unaided have been identified. Some of the best-studied
ones include basic residues 47 to 57 of the HIV-1 Tat protein,
residues 267 to 300 of herpes simplex virus type 1 VP22 tran-
scription factor, and the third -helix (residues 43 to 58) of the
Drosophila homeotic transcription domain ANTP (encoded by
the antennapedia gene) (45). These PTDs are similar to LAP
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in that they rapidly and efficiently enter cells at 37 and 4°C.
There are no sequence homologies between LAP and Tat or
ANTP PTDs, but protein structure-predicting algorithms
strongly suggest that the Tat PTD can adopt an -helix con-
formation, and the ANTP PTD corresponds to the third -he-
lix of antennapedia homeodomain (19, 46). As mentioned
above, LAP has a predicted -helix domain, and disruption of
this domain as in mutants 761 and 762 dramatically decreases
the transduction of LAP (Table 2). We have shown that LAP
can transduce fluorescein into both HeLa and Huh-7 cells. It
remains to be seen whether a LAP fusion polypeptide such as
LAP–-galactosidase, LAP-green fluorescent protein, or LAP-
luciferase could freely enter cells.
In summary, we have demonstrated here that an N-terminal
sequence from the La motif plays a critical role in recognition
by La of HCV and PV 5-UTR elements as well as IRNA.
Although this region does not interact with RNA directly,
single amino acid changes within this region drastically affect
both La’s RNA-binding and translation-stimulatory activities.
A synthetic peptide corresponding to this important region of
La is able to block RNA-protein interaction as well as stimu-
lation of viral 5-UTR-mediated translation both in vitro and in
vivo. Future studies on the mechanism of action of the peptide
should help to understand the role of the La protein in PV and
HCV IRES-mediated translation.
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